New Cancer Fighting Drug Brings Ray of Hope for Cancer Patients

By  ,  Onlymyhealth editorial team
Dec 09, 2014

Cancer Drug TrialAccording to the scientists, some dramatic results have been attained from a new type of cancer therapy. The early-phase clinical trial with breathtaking results was conducted on patients with advanced leukaemia.

A mutated form of the IDH2 gene can be found in almost 15 percent of acute myeloid leukaemia patients.

It is the IDH2 gene which usually makes a protein that plays a critical role in cell metabolism.

But, when the gene becomes mutated it can increase the production of 2-hydroxyglutarate, which is responsible for preventing immature white blood cells from developing into healthy, infection-fighting cells.

When these immature cells accumulate, they crowd out normal cells and lead to the development of acute leukaemia.

An investigational drug called AG-221 blocks the mutated IDH2 protein, allowing these immature white blood cells to develop normally.

Eytan M Stein, a medical oncologist at Memorial Sloan Kettering Cancer Centre in New York, US said "Traditional forms of cancer therapy -- surgery, chemotherapy, and radiation -- work by killing cancer cells".

Stein, who is also the lead author of the study, said "But they have major side effects since healthy cells are often also affected. Targeted therapies are much more precise".

He added "AG-221 is especially unique. Instead of inhibiting a mutation that leads to cancer cell growth, it works by targeting a gene that can transform cells into becoming healthy again".

Image courtesy: Getty Images

News source:

Read more Health News.

Is it Helpful Article?YES955 Views 0 Comment
I have read the Privacy Policy and the Terms and Conditions. I provide my consent for my data to be processed for the purposes as described and receive communications for service related information.
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK